/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Adicet Bio, Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.54 -0.0412(-4.12%) ACET at 04 Dec 2025 04:24 PM Biotechnology
Lowest Today 0.525
Highest Today 0.5602
Today’s Open 0.5602
Prev. Close 0.5601
52 Week High 1.12
52 Week Low 0.45
Day’s Range: Low 0.525 High 0.5602
52-Week Range: Low 0.45 High 1.12
1 day return -
1 Week return -17.51
1 month return -21.28
3 month return -24.31
6 month return -32.36
1 year return -47.02
3 year return -97.33
5 year return -96.13
10 year return -

Institutional Holdings

Orbimed Advisors, LLC 13.75

TANG CAPITAL MANAGEMENT LLC 9.88

RA Capital Management, LLC 9.06

Goldman Sachs Group Inc 4.51

Vanguard Group Inc 3.93

The Carlyle Group Inc 3.54

Aquilo Capital Management, LLC 2.95

Vanguard Total Stock Mkt Idx Inv 2.44

Schonfeld Strategic Advisors LLC 2.26

Renaissance Technologies Corp 1.39

Regeneron Pharmaceuticals Inc 1.16

Bridgeway Capital Management, LLC 1.08

Bridgeway Ultra-Small Company 0.97

Vanguard Institutional Extnd Mkt Idx Tr 0.89

Geode Capital Management, LLC 0.85

Alyeska Investment Group, L.P. 0.79

RBF LLC 0.74

BlackRock Inc 0.72

Millennium Management LLC 0.71

Two Sigma Advisers, LLC 0.68

Dafna Capital Management LLC 0.65

Two Sigma Investments LLC 0.62

Citadel Advisors Llc 0.55

Fidelity Extended Market Index 0.40

A4Investments SICAV SIF ACCI IlanaA2EURH 0.39

Extended Equity Market Fund K 0.17

Fidelity Total Market Index 0.13

Bridgeway Ultra-Small Company Market 0.11

Fidelity Series Total Market Index 0.10

Northern Trust Extended Eq Market Idx 0.09

NT Ext Equity Mkt Idx Fd - L 0.09

Fidelity Nasdaq Composite Index 0.09

Spartan Extended Market Index Pool F 0.08

Vanguard Instl Ttl Stk Mkt Idx InstlPls 0.08

NT Ext Equity Mkt Idx Fd - NL 0.07

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.05

Vanguard Balanced Index Inv 0.05

Spartan Total Market Index Pool G 0.05

Schwab Total Stock Market Index 0.04

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.03

Market Status

Strong Buy: 6

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 85.84 M

PB Ratio 0.9102

PE Ratio 0.0

Enterprise Value 11.78 M

Total Assets 220.22 M

Volume 3341436

Company Financials

Annual Revenue FY23:0 0.0M, FY23:24990000 25.0M, FY22:9730000 9.7M, FY21:17903000 17.9M, FY20:995000 1.0M

Annual Profit FY23:-6098000 -6.1M, FY23:24990000 25.0M, FY22:9730000 9.7M, FY21:17903000 17.9M, FY20:995000 1.0M

Annual Net worth FY23:-142658000 -142.7M, FY23:-67029000 -67.0M, FY22:-61999000 -62.0M, FY21:-36678000 -36.7M, FY20:-28138000 -28.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-1600000 -1.6M, Q2/2025:-1600000 -1.6M, Q1/2025:-1680000 -1.7M, Q3/2024:null 0.0M, Q2/2024:-1602000 -1.6M

Quarterly Net worth Q3/2025:-26856000 -26.9M, Q2/2025:-31217000 -31.2M, Q1/2025:-28214000 -28.2M, Q3/2024:-30478000 -30.5M, Q2/2024:-29901000 -29.9M

Fund house & investment objective

Company Information Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.

Organisation Biotechnology

Employees 152

Industry Biotechnology

CEO Mr. Chen Schor BA, CPA, M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow